Regulatory Submission Blog

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionSENDSEND Advantage ServicesSensible SENDSubmit

How creative should we be with SEND?

Marc Ellison

Can a certain study or data type be represented in SEND? The more ‘creative’ we need to get to place data in SEND, then potentially the less useful it is.

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SENDSubmit

SEND in 2023

Marc Ellison

What the year ahead looks like for the world of SEND.

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SEND

So, was SEND Sensible in 2022?

Marc Ellison

As 2022 ends, Marc reflects on SEND’s progress – from upcoming standards to spirited debates sparked by this blog.

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSafety PharmacologySENDSEND Advantage ServicesSensible SENDSubmit

Nervous System Tests and SEND: What’s going on?

Marc Ellison

As the nervous system data can be vital to the safety assessment, shouldn’t we include it in SEND?

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SEND

How good is good enough?

Marc Ellison

Some still believe that if a SEND submission passes the FDA’s Technical Rejection Criteria (TRC), that’s “good enough.” But this dangerously underestimates the role SEND plays in safeguarding first-in-human studies.

Stay up to Date

Get expert tips, industry news, and fresh content delivered to your inbox.